Myelodysplastic Syndromes Overview
Myelodysplastic syndromes (MDS) represent a group of different bone marrow disorders characterized by the bone marrow’s inability to produce adequate healthy blood cells. These syndromes arise due to mutations in the hematopoietic stem cells, which lead to dysfunctional blood cell production, manifesting in anemia, infections and bleeding, as immature or abnormal cells proliferate. While the exact trigger for these mutations is often unclear, factors like genetic predispositions, environmental exposures and previous chemotherapy or radiation treatments are linked to the development of MDS. Although considered rare, MDS are primarily diagnosed in older adults, with cases increasing with age. The incidence of MDS varies globally but is estimated to affect approximately 4 out of 100,000 people annually. However, this rate is likely higher in older populations, underlining the importance of understanding these complex conditions, which can progress to acute myeloid leukemia in some patients.
MDS Types
Myelodysplastic syndromes are classified into several types, depending on the nature and severity of the blood cell dysplasias.
MDS with Single Lineage Dysplasia (MDS-SLD)
In MDS-SLD, one cell lineage (red cells, white cells, or platelets) is dysplastic. It is characterized by unilineage dysplasia, meaning only one type of blood cell is affected, and these patients typically have cytopenia (a reduction in the number of mature blood cells).
MDS with Multilineage Dysplasia (MDS-MLD)
MDS-MLD involves two or more myeloid cell lines. This subtype often presents more complex symptoms since multiple types of blood cells are typically low in number and not functioning properly.
MDS with Ring Sideroblasts (MDS-RS)
When ring sideroblasts (abnormal red blood cells with rings of iron-loaded mitochondria) are present, the condition is classified as MDS-RS. There are two subtypes:
- MDS-RS with Single Lineage Dysplasia (MDS-RS-SLD): Characterized by ring sideroblasts comprising 15% or more of the marrow erythroid cells and single lineage dysplasia.
- MDS-RS with Multilineage Dysplasia (MDS-RS-MLD): This type shows dysplasia in two or more myeloid cell lines with the presence of ring sideroblasts.
MDS with Excess Blasts (MDS-EB)
MDS-EB refers to MDS subtypes with an increased number of blasts (immature cells) in the bone marrow or blood. It is further categorized into:
- MDS-EB1: With blasts comprising 5-9% of the blood or 5-10% in the bone marrow.
- MDS-EB2: Where blasts make up 10-19% of the blood or 10-20% in the bone marrow.
MDS with Isolated del(5q) Chromosome Abnormality
This subtype features a specific deletion on chromosome 5. Patients usually present with macrocytic anemia while having normal or increased platelet counts.
MDS, Unclassifiable (MDS-U)
When the criteria do not meet the above categories, the syndrome is classified as MDS-U, a less common and more ambiguous category.
In all these subtypes, there is a risk, to varying degrees, of progression to acute myeloid leukemia (AML), a potentially severe complication where the bone marrow produces a high number of immature white cells.
MDS Causes and Risk Factors
- Age: One of the most significant risk factors for MDS is age; the majority of MDS cases occur in individuals over the age of 60. This suggests that the cumulative effect of cellular damage over time may play a crucial role in the development of the disease. Environmental factors, such as tobacco smoke, pesticides and industrial chemicals like benzene, have also been implicated in the onset of MDS. Long-term exposure to these substances can lead to DNA damage within the hematopoietic cells of the bone marrow, potentially triggering MDS.
- Genetic: Genetic factors also influence the risk of developing MDS. Certain inherited genetic syndromes, such as Fanconi anemia or Shwachman-Diamond syndrome, are associated with a higher risk of MDS. Moreover, previous chemotherapy or radiation therapy for other cancers is a known risk factor. These treatments can cause mutations in the bone marrow cells that may lead to MDS, a condition sometimes referred to as "therapy-related MDS" (t-MDS).
- genetic predisposition: A small percentage of MDS cases arise from a genetic predisposition, although these are quite rare. In these instances, other family members may have a history of MDS or related blood disorders, suggesting a heritable genetic abnormality that increases susceptibility to the disease.
- Lifestyle: Lifestyle factors such as smoking and alcohol abuse may increase the risk, although their exact roles are less clearly defined. Overall, while the causes of MDS can be multifactorial and complex, understanding the risk factors is key for both prevention strategies and early detection efforts.
MDS Diagnosis
Diagnosis of MDS requires a thorough clinical evaluation and several tests. A complete blood count (CBC) is typically the first step when a hematological abnormality is suspected. Peripheral blood smear may also be examined for dysplastic changes in blood cells. If these tests indicate potential MDS, a bone marrow biopsy and aspiration become crucial. These procedures provide samples for microscopic examination and enable the identification of dysplasia in the marrow, the assessment of cellularity, and the quantification of blasts.
Cytogenetic analysis can reveal chromosomal abnormalities, like del(5q), and is integral to the classification and prognostication of MDS. Additionally, molecular genetic testing can detect gene mutations that may influence the choice of treatment and prognosis. Flow cytometry is another tool used to examine the expression of surface markers on cells, helping pathologists distinguish between MDS and other hematological disorders.
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone. We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: